AC
OREX

Ascend Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Ascend Capital’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-9,319
Closed -$572K – 264
2013
Q3 		$572K Sell
9,319
-3,045
-25% -$206K 0.02% 194
2013
Q2 		$723K Buy
+12,364
New +$761K 0.03% 164

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ascend Capital's OREX Position: Q4 2013 in Review

Ascend Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2013, closing a stake of 9,319 shares — an estimated $572K sold.

Ascend Capital first reported a position in OREX in Q2 2013 and held it in 2 quarters. The position peaked at $723K in Q2 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

  • Ascend Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • Ascend Capital sold 9,319 Orexigen Therapeutics, Inc. shares in Q4 2013, an estimated $572K.
  • Ascend Capital first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 2 quarters.
  • Ascend Capital's Orexigen Therapeutics, Inc. position peaked at $723K in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Ascend Capital's 13F filing for Q4 2013, filed 14 Feb 2014.